PharmiWeb.com - Global Pharma News & Resources

Company Directory

PharmiWeb's Pharma Company Directory is a comprehensive and searchable listing of organisations within the Pharma, Biotech & Life Sciences sector. Use it to find partner organisations, suppliers, or even a company to work for!

As an organisation, a basic listing is FREE, and can raise your profile in the industry, making you visible to thousands of monthly site visitors.

To add your organisation to the directory, simply register as a contributor and add your organisation's details. 

Note that we only accept contributions relating to the Pharma industry and that it will typically take 2 working days to approve (or otherwise) your details. Once approved, you will also be able to contribute press releases and event details to our site. Our desision is final.

Create a free account to list your company for free!

Isomerase is an innovation partner helping companies to use microbes to make anything from therapeutics to enzymes, agricultural and consumer products; sustainably, cost effectively and at scale.
The International Society for Pharmaceutical Engineering (ISPE) is the world’s largest not-for-profit association serving its members through leading scientific, technical, and regulatory advancement across the entire pharmaceutical lifecycle. The 18,000 members of ISPE are building solutions in the development and manufacture of safe, effective pharmaceutical and biologic medicines, and medical delivery devices in more than 90 countries around the world. Founded in 1980, ISPE has its worldwide headquarters and training center in North Bethesda, Maryland USA, and its operations center in Tampa, Florida USA
ICE Pharma Group was founded in the UK in 1999 to source API’s and intermediates. The company achieved early success in introducing new Indian and Chinese manufacturers to the generics sector.
Headquartered in Switzerland – a biotech-hub of Europe – Idorsia is a high-potential biopharmaceutical company, specialized in the discovery, development and commercialization of innovative small molecules, with the aim of transforming the horizon of therapeutic options.
Our company offers support services to companies that work in the pharmaceutical industry. Why is it in your best interest to choose us? We can either serve you as a service provider of a whole project or just help you in pieces of work when your staff is overloaded with tasks. You choose the scenario of the co-operation.
IgniteData is transforming the future of clinical trials through its cloud-based Virtual Research Assistant, Archer. A system-agnostic solution, Archer brings modern interoperability between EHR and key research applications, such as EDC.
As a startup, Illumina aspired to transform human health. Our initial products enabled researchers to explore DNA at an entirely new scale, helping them create the first map of gene variations associated with health, disease, and drug response. Every breakthrough opened up a new world, and showed us how much further there is to go.
We combine the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry.
ImmuPharma PLC is headquartered in London and has its research operations in France (ImmuPharma (France) SA) and Switzerland (ImmuPharma AG). ImmuPharma is dedicated to the development of innovative drugs to treat serious medical conditions.
Immuron Limited is a commercial and clinical stage publicly listed Australian biopharmaceutical company with a proprietary technology platform focused on the development and commercialization of a novel class of specifically targeted polyclonal antibodies that we believe can address significant unmet medical needs.
Immutep is a globally active biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.